
Guilford Street Laboratories (GSL), a UCL spin-out, is a contract research organization (CRO) specializing in highly precise and sensitive biomarker assays powered by machine learning-driven mass spectrometry. They offer services in proteomics, targeted lipid panels, and metabolite assays, catering to research objectives in early disease diagnosis, drug discovery, clinical trials, and personalized medicine. Their proprietary biomarker panels analyze protein, lipid, and metabolite markers. GSL's ImmunoTADA platform is a mass spectrometry-based system for quantifying antibody responses to therapies, aiming to revolutionize diagnostics for rare, cardiac, and neurodegenerative diseases. They have received an Arm's-Length Medical Grant from Chiesi Limited to advance their ImmunoTADA platform into clinical settings.

Guilford Street Laboratories (GSL), a UCL spin-out, is a contract research organization (CRO) specializing in highly precise and sensitive biomarker assays powered by machine learning-driven mass spectrometry. They offer services in proteomics, targeted lipid panels, and metabolite assays, catering to research objectives in early disease diagnosis, drug discovery, clinical trials, and personalized medicine. Their proprietary biomarker panels analyze protein, lipid, and metabolite markers. GSL's ImmunoTADA platform is a mass spectrometry-based system for quantifying antibody responses to therapies, aiming to revolutionize diagnostics for rare, cardiac, and neurodegenerative diseases. They have received an Arm's-Length Medical Grant from Chiesi Limited to advance their ImmunoTADA platform into clinical settings.
Founded: 2023 (UCL spin-out)
Focus: ML-driven mass spectrometry biomarker assays (proteins, lipids, metabolites)
Location: 30 Guilford St, London
Recent funding: Pre-seed announced 2024-05-17 led by GS Verde Group
Platform: ImmunoTADA — mass spectrometry-based antibody response quantification
Biomarker measurement for diagnostics, clinical trials, drug discovery, and precision medicine.
2023
Biotechnology Research
Pre-seed round announced May 17, 2024; GS Verde Group listed as lead/sole investor.
“GS Verde Group led the pre-seed round announced May 17, 2024”
| Company |
|---|
Location : London, United Kingdom
Reports to : Senior Scientist
Salary : Competitive
Hours of Work : 40 per week
Multiple Roles Open
About The Company:
At GSL, our mission is to revolutionise biomarker discovery and development by harnessing the power of machine learning (ML). We are dedicated to improving diagnostics and advancing treatment options in rare, cardiac, and neurodegenerative disease. Through cutting-edge ML algorithms, we develop panels of biomarkers that can be used to diagnose, stratify and monitor patients across the entire clinical development pathway.
Our commitment is to empower healthcare professionals with the tools they need to provide precise diagnoses, enable the development of next-generation treatments, and improve accuracy levels across the entire clinical development pathway, ultimately saving lives and enhancing the quality of care worldwide.
Our Culture And Values:
Within GSL, we have a culture and value set that isn’t just a paragraph or a mission statement. Our team all share a passion of wanting to make a real difference in our work, and to go above and beyond what is expected of us. We will always use our collective knowledge to advise where appropriate and add as much value as possible to the work that we undertake. In order to achieve this our teams will always focus on the below methods to ensure we always deliver the best possible outcomes for our customers and patients.
Job Description:
Skills/ Experience Requirements